AJR Am J Roentgenol

1. CHOI WP, Almaguel FG, Franquet-Elia E, Ghai S, et al
   Optimal Imaging Strategies After Negative PSMA PET/CT Results in Patients With Prostate Cancer Biochemical Recurrence: AJR Expert Panel Narrative Review.
   AJR Am J Roentgenol. 2026 Jul 15. doi: 10.2214/AJR.26.35081.
   

   >> Share

   
   

   
   BJU Int

2. LIU L, Huang JF, Shi RH, Yang L, et al
   Automated recognition of surgical phases in robot-assisted radical prostatectomy using a Hiera-based vision transformer.
   BJU Int. 2026;138:324-333.
   

   >> Share

   
   
3. CARLL J, Walbaum J, Delgado C, Berg E, et al
   Guideline of guidelines: pelvic lymph node dissection at time of radical prostatectomy.
   BJU Int. 2026;138:208-218.
   

   >> Share

   
   

   
   BMC Cancer

4. AKINNOLA OO, Olaniyan AI, Adeboye BA, Akinyosoye AD, et al
   Impact of immunotherapy as a monotherapy or in combination with conventional therapies on regulatory T-cell (Treg) modulation in prostate cancer: a systematic review.
   BMC Cancer. 2026 Jul 17. doi: 10.1186/s12885-026-16550.
   

   >> Share

   
   
5. NGUYEN HT, Vu MD, Nguyen DD, Dinh PN, et al
   Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients.
   BMC Cancer. 2026;26:858.
   

   >> Share

   
   

   
   BMC Urol

6. DE ALMEIDA LUZ M, Pereira J, Kool R, Matheus WE, et al
   Biochemical recurrence following definitive treatment of prostate cancer in Brazil: a retrospective cohort study.
   BMC Urol. 2026 Jul 13. doi: 10.1186/s12894-026-02249.
   

   >> Share

   
   

   
   Br J Cancer

7. PENG Z, Hodgson K, Fisher M, Mei S, et al
   Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.
   Br J Cancer. 2026 Jul 13. doi: 10.1038/s41416-026-03544.
   

   >> Share

   
   

   
   Cancer Lett

8. LIANG S, Zheng Y, Wu X, Ji F, et al
   A novel lncRNA HUDRPC suppresses ferroptosis via the DDX5/DDIT3 pathway to promote docetaxel resistance in prostate cancer.
   Cancer Lett. 2026;657:218727.
   

   >> Share

   
   

   
   Clin Cancer Res

9. WEBB AJ, Harper E, Rattay T, Aguado-Barrera ME, et al
   Circadian genotypes in PER3 and time of prostate cancer radiotherapy interact to affect risk of late side-effects.
   Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-26-0268.
   

   >> Share

   
   

   
   Eur Urol

10. SHORE ND, Freedland SJ
    Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.019.
    Eur Urol. 2026 Jul 10:S0302-2838(26)02156-1. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
11. HE BM, Zhang K, Zhou Z, Chen X, et al
    Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION).
    Eur Urol. 2026 Jul 10:S0302-2838(26)02243-8. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
12. LIGHT A, Peters M, Gopalakrishnan A, Mayor N, et al
    Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries.
    Eur Urol. 2026 Jul 10:S0302-2838(26)02169-X. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
13. SHIN YS, Kim JH
    Re: David-Dan Nguyen, Borna Tadayon Najafabadi, Lauren Lin, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controll
    Eur Urol. 2026 Jul 11:S0302-2838(26)02255-4. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
14. KRILAVICIUTE A, Becker N, Carlsson SV, Kaaks R, et al
    Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-Aged Men - Data from the PROBASE Trial.
    Eur Urol. 2026 Jul 13:S0302-2838(26)02239-6. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
15. HEIDEGGER I
    Re: Luka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al. IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.014.
    Eur Urol. 2026 Jul 13:S0302-2838(26)02257-8. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
16. MESSINA E, Sciarra A, La Torre G, Panebianco V, et al
    Re: De Luca et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2026;89:246-57.
    Eur Urol. 2026 Jul 14:S0302-2838(26)02234-7. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
17. CORNFORD P, van den Bergh RCN, Briers E, Chiu P, et al
    EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Eur Urol. 2026 Sep 1:S0302-2838(26)02114-7. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
18. TILKI D, van den Bergh RCN, Briers E, Chiu P, et al
    EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Eur Urol. 2026 Jul 15:S0302-2838(26)02116-0. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
19. O'CALLAGHAN ME, Selth L, Wittert G
    Re: Testosterone Treatment in Prostate Cancer Survivors with Hypogonadism: A Randomized Clinical Trial.
    Eur Urol. 2026 Jul 15:S0302-2838(26)02262-1. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
20. BELLIVEAU C, Kishan AU, Calais J, Plouznikoff N, et al
    Re: [177Lu]-PSMA-617-PSMA-617 in Oligometastatic Hormone Sensitive Prostate Cancer (BULLSEYE): An Open-label, Randomised, Phase 2 Study.
    Eur Urol. 2026 Jul 15:S0302-2838(26)02264-5. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
21. URSO L, Giannarini G, Girometti R, Crestani A, et al
    Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial.
    Eur Urol. 2026 Jul 16:S0302-2838(26)02268-2. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
22. MAY M, Burger M, Brookman-May SD
    Re: Prostate-specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer.
    Eur Urol. 2026 Jul 16:S0302-2838(26)02261-X. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
23. AL-KHANATY A, Delgado C, Berg E, Sandhu K, et al
    RE: Perioperative Apalutamide in High-Risk Localized Prostate Cancer.
    Eur Urol. 2026 Jul 16:S0302-2838(26)02260-8. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    

    
    Int J Oncol

24. BAXEVANIS CN, Stokidis S, Fortis SP, Goulielmaki M, et al
    Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).
    Int J Oncol. 2026;69:104.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

25. COZZI S, Brenna D, Vial N, Roukoz C, et al
    Beyond Prostate-Specific Antigen and Conventional Imaging: How Prostate-Specific Membrane Antigen Positron Emission Tomography Is Transforming Postradiation Therapy Monitoring in Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2026;125:1466-1470.
    

    >> Share

    
    
26. POON DM, Wong K, Lam D, Johnson D, et al
    Acute toxicity and quality of life with stereotactic body radiotherapy versus conventional fractionated intensity-modulated radiotherapy to the prostate and pelvis in high-risk prostate cancer (SRAM): A randomized phase II trial.
    Int J Radiat Oncol Biol Phys. 2026 Jul 10:S0360-3016(26)03941.
    

    >> Share

    
    
27. LALL R, Evans M, Seo Y, Niknejad A, et al
    Continuous, Preclinical Activity Reconstruction in (177)Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated gamma-Sensor Network.
    Int J Radiat Oncol Biol Phys. 2026;125:1522-1533.
    

    >> Share

    
    
28. SINGH M, Ghosh S, Katdare A, Agrawal A, et al
    PSA and PSMA Kinetics After PSMA-PET and MR Guided Prostate Stereotactic Body Radiation Therapy With Focal Boost: Results From the Phase 2 PROBE Trial.
    Int J Radiat Oncol Biol Phys. 2026;125:1471-1479.
    

    >> Share

    
    

    
    Int J Urol

29. SAKAMOTO S, Yamamoto K, Yamamoto H, Hatakeyama S, et al
    A Nationwide Descriptive Analysis of Real-World Outcomes After Radical Prostatectomy in Japan Using the National Clinical Database.
    Int J Urol. 2026;33:e70567.
    

    >> Share

    
    
30. MATSUO T, Ozawa Y, Yorozu A, Hattori S, et al
    Prognostic Impact and Metastasis Propensity of Grade Group 5 Prostate Cancer Following Permanent Seed Implantation Brachytherapy-Based Trimodality Therapy: Implications for Intensified Staging and Systemic Therapy Optimization.
    Int J Urol. 2026;33:e70574.
    

    >> Share

    
    

    
    Invest Radiol

31. KADER A, Mangarova DB, Godde H, Ranner-Hafferl MLHH, et al
    Elastin-Specific Molecular Magnetic Resonance Imaging Reveals Spatiotemporal Extracellular Matrix Remodeling at the Tumor-Stroma Interface During Prostate Cancer Progression.
    Invest Radiol. 2026 Jul 15. doi: 10.1097/RLI.0000000000001302.
    

    >> Share

    
    

    
    J Nucl Med

32. RAVI P, Zhong C, Perez KJ, Xie W, et al
    Clinical Impact and Dynamics of Clonal Hematopoiesis with (177)Lu-PSMA-617 Therapy in Advanced Prostate Cancer.
    J Nucl Med. 2026 Jul 16:jnumed.126.272125. doi: 10.2967/jnumed.126.272125.
    

    >> Share

    
    
33. HERRMANN K, Rahbar K, Eiber M, Sparks R, et al
    Update to "Renal and Multiorgan Safety of (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy".
    J Nucl Med. 2026 Jul 16:jnumed.126.265448e. doi: 10.2967/jnumed.126.265448.
    

    >> Share

    
    
34. MIYAHIRA A, Czernin J
    An Immunologist's Path Toward Advancing the Scientific Mission of the Prostate Cancer Foundation: Andrea Miyahira Talks with Johannes Czernin About the Role of the Prostate Cancer Foundation and Cancer Treatment.
    J Nucl Med. 2026 Jul 16:jnumed.126.273264. doi: 10.2967/jnumed.126.273264.
    

    >> Share

    
    

    
    J Urol

35. TANEJA SS
    Updating of the AUA/ASTRO prostate cancer guidelines - a constant work in progress.
    J Urol. 2026 Jul 17:101097JU0000000000005225. doi: 10.1097/JU.0000000000005225.
    

    >> Share

    
    
36. SCARPATO KR, Cookson MS, Dreicer R, Sayan M, et al
    Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026). Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2026 Jul 16:101097JU0000000000005219. doi: 10.1097/JU.0000000000005219.
    

    >> Share

    
    
37. SCARPATO KR, Cookson MS, Dreicer R, Sayan M, et al
    Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer.
    J Urol. 2026 Jul 16:101097JU0000000000005220. doi: 10.1097/JU.0000000000005220.
    

    >> Share

    
    

    
    Oncogene

38. YANG R, Ge Q, Wu F, Long M, et al
    METTL5-mediated rRNA modification controls prostate cancer progression through the IRF7/DNA2 axis and mitophagy regulation.
    Oncogene. 2026 Jul 13. doi: 10.1038/s41388-026-03867.
    

    >> Share

    
    

    
    PLoS One

39. AKYNKOZHAYEV B, Christoffersen B, Lantz A, Nordstrom T, et al
    Joint modelling of PSA dynamics and prostate cancer risks: A population-based study in men without prior prostate cancer.
    PLoS One. 2026;21:e0343751.
    

    >> Share

    
    

    
    Prostate

40. ONISHI K, Nakahama T, Nakai Y, Tachibana A, et al
    Evaluating Risk Factors Associating With Late Recurrence After Low-Dose-Rate Brachytherapy for Prostate Cancer Using Machine Learning.
    Prostate. 2026 Jul 16. doi: 10.1002/pros.70219.
    

    >> Share

    
    

    
    Radiol Artif Intell

41. JAISWAL A, Rinneburger M, Meyer F, Arjune S, et al
    Impact on Cost and Expert Time of Data-Efficient Deep Learning for Medical Image Segmentation.
    Radiol Artif Intell. 2026;8:e250200.
    

    >> Share

    
    

    
    Urol Int

42. MELCHIOR F, Koett M, Aigner G, Schroffenegger J, et al
    Real-World Use of Prolaris(R) to Guide Treatment Decisions in Localized Prostate Cancer Eligible for Active Surveillance.
    Urol Int. 2026 Jul 17:1-14. doi: 10.1159/000553659.
    

    >> Share

    
    

    
    Urology

43. BLANCAFLOR A, Ochsner A, Glebocki R, Westrick L, et al
    Immediate Release of Prostate Biopsy Results: Perspectives From Patients and Providers.
    Urology. 2026;213:96-100.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share